AMEX · Biotechnology

Cybin Inc. (CYBN) Stock

$8.28 +1.22% AMEX: CYBN Healthcare

Cybin Inc. is a biopharmaceutical firm dedicated to pioneering treatments that leverage psychedelic compounds.

Valuation

MetricValue
Price$8.28
Market Cap$413.02M
P/E Ratio-1.67
P/B Ratio1.50
P/S Ratio0.00
EPS (TTM)$-0.61
52-Week High$10.72
52-Week Low$4.81
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-72.37%
ROA-58.36%
ROCE-63.74%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio9.52

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$0$0$0$0
Operating Profit$-31.0M$-64.0M$-52.0M$-79.0M$-143.0M
Net Profit$-32.0M$-71.0M$-40.0M$-78.0M$-113.0M
EPS$-3221645.62$-0.43$-0.22$-9.41$-0.61
Op Margin-3592.0%————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$92.0M$84.0M$54.0M$302.0M$259.0M
Total Liabilities$6.0M$6.0M$8.0M$10.0M$21.0M
Cash$64.0M$54.0M$17.0M$209.0M$135.0M
Borrowings$0$0$0$0$0

Latest News

Faraday Future Showcases Its EAI Robot World Across Three High-Level Silicon Valley Robotics and AGI Summits, Drawing Strong Developer Interest and Advancing Its New "Four-Core Full-Stack AI" Ecosystem Strategy Business Wire · Jul 17, 2026 Netflix Reported Record Quarterly Revenue of $12.6 Billion, but Guidance Came in Below Expectations. Here’s What It Means for Investors. Motley Fool · Jul 17, 2026 HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027 PR Newswire · Jul 17, 2026 To air or not to air? Nation's TV networks struggle to find the right balance for Trump speech Associated Press · Jul 17, 2026 Altinteg Strengthens Compliance-Ready Traceability For Food Operations GlobeNewswire · Jul 17, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-19.0M$-19.0M$-45.0M$-69.0M$-101.0M
Investing Cash Flow$-1.0M$-1.0M$-4.0M$6.0M$-4.0M
Financing Cash Flow$6.0M$0$0$0$0
Net Cash Flow$62.0M$-10.0M$-37.0M$192.0M$-74.0M
Free Cash Flow$-19.0M$-19.0M$-46.0M$-70.0M$-103.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.07
EV / EBITDA-0.07
FCF Yield-75.57%
Quick Ratio9.52
Interest Coverage-49.90
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALEC $1.52 +0.33% -1.58 $168.20M 0.00%
IMDXInsight Molecular Diagnostics Inc. $4.70 -0.84% -3.13 $151.76M 0.00%
IPHAInnate Pharma S.A. $1.79 +0.14% -2.89 $168.32M 0.00%
MIST $1.13 -2.59% -2.00 $97.05M 0.00%
MOLNMolecular Partners AG $3.91 -2.25% -2.08 $146.67M 0.00%

About Cybin Inc.

Cybin Inc. is a biopharmaceutical firm dedicated to pioneering treatments that leverage psychedelic compounds. Its research and development portfolio encompasses several key candidates: CYB003, a modified psilocybin compound targeting major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine designed to alleviate anxiety conditions; and CYB005, a phenethylamine derivative aimed at combating neuroinflammation. Beyond its drug pipeline, Cybin has also conceived EMBARK, an innovative form of psychotherapy enhanced by psychedelics. The enterprise's primary base of operations is situated in Toronto, Canada.

Cybin Inc. is headquartered in CA.

Cybin Inc. (CYBN) stock trades at $8.28 with a market capitalization of $413.02M. The stock is valued at a price-to-earnings (P/E) ratio of -1.67, price-to-book of 1.50, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $4.81 and $10.72, and currently trades 22.8% below its 52-week high.

On profitability, Cybin Inc. generates a return on equity (ROE) of -72.37%, return on capital employed of -63.74%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.cybin.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides